A lucrative licensing agreement deal was announced on 12 October between US-based Karyopharm Therapeutics and Japan’s Ono Pharmaceutical for the development and commercialization of Karyopharm’s lead novel compound selinexor and KPT-8602, which are indicated for all oncology indications for Japan, South Korea, Taiwan, Hong Kong and AESEAN countries.

Ono Pharmaceutical is well-respected Japanese company for commercialization and partnerships and has had a total of 29 licensing agreement and partnership deals over the last five years. The graph below shows a sharp peak in these deals for Ono Pharmaceutical in 2017 with a total of eight licensing agreements and partnership deals.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

While the US still leads the way in terms of licensing agreements and partnership deals, Japanese companies like Ono Pharmaceutical have found a strong position the market.

Source: GlobalData Pharma Intelligence Center, Deals Database [accessed October 2017]

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.